RTTNews | Jan 8, 2021 09:06AM EST

09:05 Friday, January 8, 2021 (RTTNews.com) - Ultragenyx: Durable Response Reported From Phase 1/2 Studies Of DTX401 For GSDIa And DTX301 For OTC

For comments and feedback: contact editorial@rttnews.com

https://www.rttnews.comCopyright(c) 2021 RTTNews.com All Rights Reserved